HK Stock MarketDetailed Quotes

01801 INNOVENT BIO

Watchlist
  • 38.550
  • +0.400+1.05%
Not Open Apr 25 16:09 CST
62.55BMarket Cap-55150P/E (TTM)

About INNOVENT BIO Company

Cinda Biopharmaceuticals is a biopharmaceutical company dedicated to developing, manufacturing and selling high-quality innovative drugs that ordinary people can afford to use. The company was founded by Dr. Yu Dechao in 2011 and has built a multi-functional fully integrated biopharmaceutical platform that meets global quality standards, integrating R&D, clinical development, CMC and commercialization capabilities. The company has established a rich product pipeline, covering a series of innovative therapeutic targets and drug forms (including monoclonal antibodies, multi-specific antibodies, immune cytokines, fusion proteins, T-cell conjugators, antibody-conjugated drugs, cell therapy, small molecule drugs, etc.), covering various major disease fields such as oncology, cardiovascular and metabolic, immunology, and ophthalmology. The product pipeline has huge clinical and commercial potential as a single drug or combination therapy to meet a broad range of medical needs. The company has reached 30 strategic collaborations with international partners such as Eli Lilly, Roche Group, Sanofi, Adimab, Incyte, and the University of Texas Anderson Cancer Center. The company hopes to work with everyone to promote the development of the biopharmaceutical industry, improve the accessibility of medicines and the quality of life for patients.

Company Profile

Symbol01801
Company NameINNOVENT BIO
ISINKYG4818G1010
Listing DateOct 31, 2018
Issue Price13.98
Shares Offered236.35M share(s)
FoundedApr 28, 2011
Registered AddressCayman Islands
Chairmandechao yu
Secretaryyanjuchenluoer wang
Audit InstitutionDeloitte & Touche Tohmatsu Certified Public Accountants
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeMaples Corporate Services Limited PO Box 309, Ugland House, Grand Cayman KY1-1104 Cayman Islands
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden Phase I, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees4872
MarketHong Kong motherboard
Phone(86)051269566088
Fax(86)0512695660888348
Emailir@innoventbio.com
Business Cinda Biopharmaceuticals is an investment holding company mainly engaged in biopharmaceuticals. The company and its subsidiaries are engaged in the research and development of antibody and protein pharmaceutical products, the sale and distribution of pharmaceuticals, and the provision of consulting and R&D services. The company's main product is dabercib (cindilizumab injection), which is used to treat recurrent or refractory classic Hodgkin lymphoma. The company's products also include the adalimumab antibiotic analogue IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis. IBI-305, an antibiotic similar to bevacizumab, is used to treat metastatic colorectal cancer and advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC). IBI-301, an antibiotic similar to rituximab, is used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company's products are used in the fields of oncology, metabolism, immunology and fundus diseases.

Company Executives

  • Name
  • Position
  • Salary
  • dechao yu
  • President,CEOs,presidencies,Executive Director,Chairman of the Nomination Committee,Chairman of the Strategy Committee,Remuneration Committee Members
  • --
  • hao xi
  • Executive Director,Strategy Committee Members,Authorized Representative
  • --
  • Charles Leland Cooney
  • Independent Non-Executive Director,Nomination Committee Members,Audit Committee Members,Strategy Committee Members
  • --
  • yiyin xu
  • Independent Non-Executive Director,Chairman of the Audit Committee,Remuneration Committee Chairman
  • --
  • kaixian chen
  • Independent Non-Executive Director,Audit Committee Members,Remuneration Committee Members,Nomination Committee Members
  • --
  • Gary Zieziula
  • Independent Non-Executive Director,Strategy Committee Members,Audit Committee Members
  • --
  • shun lu
  • Independent Non-Executive Director,Strategy Committee Members
  • --
  • yanju wang
  • Joint Company Secretary
  • --
  • luoer chen
  • Joint Company Secretary,Authorized Representative
  • --
  • fei you
  • chief financial officer
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg